Review of Current Guidelines on the Care of Postherpetic Neuralgia
- 1 September 2011
- journal article
- review article
- Published by Taylor & Francis Ltd in Postgraduate Medicine
- Vol. 123 (5), 134-142
- https://doi.org/10.3810/pgm.2011.09.2469
Abstract
An unfortunate minority of patients with acute herpes zoster (AHZ) experience pain beyond the typical 4-week duration, and roughly 10% develop the distressing complication of postherpetic neuralgia (PHN), often defined as pain persisting for > 4 months after the onset of the rash. Elderly patients are at increased risk of PHN. The pathophysiology of PHN is complex, likely involving both peripheral and central processes. This complexity may create opportunities for pharmacologic interventions with multiple differing mechanisms of action. Consequently, complementary combinations of pharmacologic agents are frequently more effective than any monotherapy. Current US and international guidelines on the care of patients with PHN are reviewed and interpreted here to facilitate their effective incorporation into the practice of primary care physicians, acknowledging the contrasts that often exist between the clinical trial populations analyzed to craft so-called evidence-based medicine and the individual patients seen in daily practice, many of whom may not have been candidates for those clinical trials. First-line treatments for PHN include tricyclic antidepressants, gabapentin and pregabalin, and the topical lidocaine 5% patch. Opioids, tramadol, capsaicin cream, and the capsaicin 8% patch are recommended as either second- or third-line therapies in different guidelines. Therapies that have demonstrated effectiveness for other types of neuropathic pain are discussed, such as serotonin-norepinephrine reuptake inhibitors, the anticonvulsants carbamazepine and valproic acid, and botulinum toxin. Invasive procedures such as sympathetic blockade, intrathecal steroids, and implantable spinal cord stimulators have been studied for relief of PHN, mainly in patients refractory to noninvasive pharmacologic interventions. The main guidelines considered here are those issued by the American Academy of Neurology for the treatment of postherpetic neuralgia (2004) and general guidelines for the treatment of neuropathic pain issued by the Special Interest Group on Neuropathic Pain of the International Association for the Study of Pain (2007) and the European Federation of Neurological Societies (2010).Keywords
This publication has 69 references indexed in Scilit:
- EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revisionEuropean Journal of Neurology, 2010
- Recommendations for the Pharmacological Management of Neuropathic Pain: An Overview and Literature UpdateMayo Clinic Proceedings, 2010
- A Case of Human Immunodeficiency Virus Infection Initially Presented with Disseminated Herpes ZosterAnnals of Dermatology, 2010
- The Effectiveness of Repetitive Paravertebral Injections with Local Anesthetics and Steroids for the Prevention of Postherpetic Neuralgia in Patients with Acute Herpes ZosterAnesthesia & Analgesia, 2009
- The Incidence and Clinical Characteristics of Herpes Zoster Among Children and Adolescents After Implementation of Varicella VaccinationThe Pediatric Infectious Disease Journal, 2009
- Efficacy, Safety, and Tolerability of Pregabalin Treatment for Painful Diabetic Peripheral NeuropathyDiabetes Care, 2008
- Vaccination against Herpes Zoster and Postherpetic NeuralgiaThe Journal of Infectious Diseases, 2008
- Relief of post-herpetic neuralgia by surgical removal of painful skin: 5 years laterPain, 2007
- Analgesic Therapy in Postherpetic Neuralgia: A Quantitative Systematic ReviewPLoS Medicine, 2005
- Topical capsaicin treatment of chronic postherpetic neuralgiaJournal of the American Academy of Dermatology, 1989